Cosmo Bio Co., Ltd. (3386) AI Stock Analysis

• Market Cap: ¥6.83B
• Dividend Yield: 5.2%
• Average Volume (3M): 3.22K
• Price to Earnings (P/E): 27.7
• Beta (1Y): 0.28
• Revenue Growth: 7.74%
• EPS Growth: -39.17%
• Country: JP
• Employees: 174
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 37.22
• Shares Outstanding: 6,048,000
• 10 Day Avg. Volume: 2,140
• 30 Day Avg. Volume: 3,216
• PEG Ratio: -5.11
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ¥1,257.00 ▲(6.08%Upside)

Cosmo Bio Co., Ltd.'s overall stock score is driven primarily by its strong financial stability, despite challenges in profitability and cash flow. The stock's technical indicators suggest overbought conditions, posing a risk of short-term correction. High P/E ratio indicates potential overvaluation, though the attractive dividend yield offers some compensating benefit.

Cosmo Bio Co., Ltd. Business Overview & Revenue Model

Company Description

Cosmo Bio Co., Ltd. (3386) is a Japan-based company primarily engaged in the distribution and sale of life science research products. The company offers a comprehensive range of reagents, instruments, and consumables for biotechnology and life science research. Cosmo Bio Co., Ltd. focuses on providing high-quality products sourced from both domestic and international manufacturers, catering to the needs of academic institutions, research laboratories, and pharmaceutical companies.

How the Company Makes Money

Cosmo Bio Co., Ltd. generates revenue through the sale of life science research products, including reagents, instruments, and consumables. The company partners with a variety of manufacturers worldwide to distribute their products in Japan. Key revenue streams include direct sales to research institutions and laboratories, as well as partnerships with international suppliers that allow Cosmo Bio to offer a diverse product range. The company also benefits from its established relationships with academic and pharmaceutical sectors, ensuring a steady demand for its products. Additionally, Cosmo Bio may engage in exclusive distribution agreements or collaborations with manufacturers to enhance its product offerings and maintain its competitive edge in the life sciences market.

Cosmo Bio Co., Ltd. Financial Statement Overview

Summary

Cosmo Bio Co., Ltd. exhibits a stable financial position with strong equity and low leverage, as evidenced by a high equity ratio and low debt-to-equity ratio. However, the company faces declining profitability and cash flow metrics, with a significant decrease in net profit margin and free cash flow, necessitating improvements in operational efficiency.

Income Statement

Cosmo Bio Co., Ltd. has shown a stable revenue growth over the years with a slight decrease in the latest year. Gross Profit Margin remains strong at 33.17% for 2024, reflecting efficient cost management. However, the net profit margin has decreased to 2.61% in 2024 from 4.73% in 2023, indicating increased expenses or reduced profitability. EBIT and EBITDA margins are lower compared to previous years, suggesting reduced operational efficiency.

Balance Sheet

The company's balance sheet is robust with a high equity ratio of 76.44% in 2024, indicating low leverage and financial stability. The Debt-to-Equity ratio is exceptionally low at 0.0022, which is favorable. Return on Equity has decreased to 2.92% in 2024 from 5.23% in 2023, suggesting reduced profitability relative to equity.

Cash Flow

Free Cash Flow has decreased significantly by 96.07% from 2023 to 2024, indicating potential cash flow issues. Operating Cash Flow to Net Income ratio is 0.92, suggesting good cash generation relative to net income. The Free Cash Flow to Net Income ratio is low at 0.10, reflecting less efficient cash conversion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.04B	9.34B	9.55B	9.23B	8.09B
Gross Profit	3.33B	3.25B	3.44B	3.66B	3.15B
EBITDA	455.00M	669.00M	958.00M	1.22B	928.00M
Net Income	262.00M	442.00M	517.00M	737.00M	674.00M
Balance Sheet
Total Assets	11.72B	10.87B	10.31B	10.07B	9.64B
Cash, Cash Equivalents and Short-Term Investments	2.69B	3.02B	3.04B	3.56B	3.26B
Total Debt	20.00M	20.00M	20.00M	20.00M	20.00M
Total Liabilities	2.17B	1.85B	1.70B	1.75B	1.78B
Stockholders Equity	8.97B	8.45B	8.05B	7.79B	7.36B
Cash Flow
Free Cash Flow	25.00M	636.00M	180.00M	507.00M	738.00M
Operating Cash Flow	241.00M	736.00M	284.00M	648.00M	803.00M
Investing Cash Flow	-217.00M	-758.00M	-291.00M	-145.00M	42.00M
Financing Cash Flow	-479.00M	-201.00M	-236.00M	-420.00M	-97.00M

Cosmo Bio Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1185.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Positive. The current price of 1185 is above the 20-day moving average (MA) of 1180.70, above the 50-day MA of 1153.96, and above the 200-day MA of 1108.81, indicating a bullish trend. The MACD of 8.40 indicates Positive momentum. The RSI at 60.12 is Neutral, neither overbought nor oversold. The STOCH value of 80.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3386.

Cosmo Bio Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2395	76 Outperform	¥58.16B	11.81		3.62%	22.55%	-10.96%
3386	64 Neutral	¥6.83B	27.75		5.20%	7.74%	-39.17%
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
4588	44 Neutral	¥14.56B	―		―	11.93%	15.04%
4882	42 Neutral	¥6.00B	―		―	16.18%	31.67%
4586	41 Neutral	¥4.11B	―		―	773.28%	35.71%
4893	41 Neutral	¥7.57B	―		―	-97.61%	14.80%